1. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats

   • Pius Maliakal
   • Maen Abdelrahim
   • Riyaz Basha

   PRECLINICAL STUDIES 04 January 2011 Pages: 853 - 861

   

2. Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K562

   • Masaharu Hazawa
   • Michiko Kudo
   • Ikuo Kashiwakura

   PRECLINICAL STUDIES 05 January 2011 Pages: 862 - 869

   

3. Antimetastatic activity and low systemic toxicity of tetradecyl gallate in a preclinical melanoma mouse model

   • Claudriana Locatelli
   • Deborah Regina Carvalho
   • Tânia Beatriz Creczynski-Pasa

   PRECLINICAL STUDIES 08 January 2011 Pages: 870 - 879

   

4. A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines

   • Jessica Castro
   • Marc Ribó
   • Antoni Benito

   PRECLINICAL STUDIES 01 February 2011 Pages: 880 - 888

   

5. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83

   • Xiangrui Liu
   • Frankie Lam
   • Shudong Wang

   PRECLINICAL STUDIES 18 February 2011 Pages: 889 - 897

   

6. Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol

   • Annegret Serwe
   • Kristina Rudolph
   • Gerhard Erkel

   PRECLINICAL STUDIES 22 February 2011 Pages: 898 - 915

   

7. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice

   • Grace-Ifeyinwa Onimoe
   • Aiguo Liu
   • Jiayuh Lin

   PRECLINICAL STUDIES 22 February 2011 Pages: 916 - 926

   

8. Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model

   • Uwe Pohlen
   • Heinz J. Buhr
   • Christoph Holmer

   PRECLINICAL STUDIES 01 March 2011 Pages: 927 - 935

   

9. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

   • Timothy P. Burkholder
   • Joshua R. Clayton
   • James J. Starling

   PRECLINICAL STUDIES 01 March 2011 Pages: 936 - 949

   

10. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057

    • John A. Hartley
    • Anzu Hamaguchi
    • Philip W. Howard

    PRECLINICAL STUDIES 08 March 2011 Pages: 950 - 958

    

11. Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens

    • Danilo D. Rocha
    • Aruna Balgi
    • Claudia Pessoa

    PRECLINICAL STUDIES 18 March 2011 Pages: 959 - 966

    

12. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2

    • Alicia A. Goyeneche
    • Erin E. Seidel
    • Carlos M. Telleria

    PRECLINICAL STUDIES Open access 22 March 2011 Pages: 967 - 980

    

13. In vivo toxicity study of N-1-sulfonylcytosine derivatives and their mechanisms of action in cervical carcinoma cell line

    • Jelena Kašnar-Šamprec
    • Ivana Ratkaj
    • Biserka Žinić

    PRECLINICAL STUDIES 22 March 2011 Pages: 981 - 990

    

14. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes

    • Berta Otová
    • Iwao Ojima
    • Ivan Gut

    PRECLINICAL STUDIES 30 March 2011 Pages: 991 - 1002

    

15. Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death

    • David R. Vásquez
    • Julien Verrax
    • Pedro Buc Calderon

    PRECLINICAL STUDIES 05 April 2011 Pages: 1003 - 1011

    

16. A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen

    • Dennis Ma
    • Phillip Tremblay
    • Siyaram Pandey

    PRECLINICAL STUDIES 15 April 2011 Pages: 1012 - 1027

    

17. Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways

    • Gili Berkovitch-Luria
    • Michal Weitman
    • Zvi Malik

    PRECLINICAL STUDIES 21 April 2011 Pages: 1028 - 1038

    

18. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

    • Amye Tevaarwerk
    • George Wilding
    • Glenn Liu

    PHASE I STUDIES 12 January 2011 Pages: 1039 - 1045

19. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

    • Masashi Niwakawa
    • Katsuyoshi Hashine
    • Yoshiteru Sumiyoshi

    PHASE I STUDIES 19 January 2011 Pages: 1046 - 1054

    

20. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

    • Yutaka Fujiwara
    • Naomi Kiyota
    • Hironobu Minami

    PHASE I STUDIES Open access 08 February 2011 Pages: 1055 - 1064

    

21. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

    • Michael Millward
    • Paul Mainwaring
    • Matthew A. Spear

    PHASE I STUDIES 16 February 2011 Pages: 1065 - 1073

    

22. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

    • Steven J. O’Day
    • Anna C. Pavlick
    • Brenda Foster

    PHASE I STUDIES 18 February 2011 Pages: 1074 - 1081

    

23. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer

    • Elwyn C. Cabebe
    • George A. Fisher
    • Branimir I. Sikic

    PHASE I STUDIES 15 March 2011 Pages: 1082 - 1087

24. A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors

    • Kyle Holen
    • Robert DiPaola
    • Mark Stein

    PHASE I STUDIES 22 March 2011 Pages: 1088 - 1095

    

25. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

    • Akira Fukutomi
    • Kiyohiko Hatake
    • Nobuyuki Yamamoto

    PHASE I STUDIES 12 April 2011 Pages: 1096 - 1106

    

26. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

    • H. M. Kantarjian
    • S. Padmanabhan
    • M. Minden

    PHASE I STUDIES 15 April 2011 Pages: 1107 - 1115

    

27. Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials

    • Antonin Levy
    • Laurence Albiges-Sauvin
    • Jean-Charles Soria

    PHASE I STUDIES 21 April 2011 Pages: 1116 - 1120

28. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

    • Simona Lapusan
    • Maria B. Vidriales
    • Jean-Pierre Marie

    PHASE I STUDIES 26 April 2011 Pages: 1121 - 1131

    

29. Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer

    • Isamu Okamoto
    • Nobuyuki Yamamoto
    • Kazuhiko Nakagawa

    PHASE I STUDIES 03 May 2011 Pages: 1132 - 1137

    

30. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

    • Dirk Strumberg
    • Beate Schultheis
    • K. Mross

    PHASE II STUDIES 21 December 2010 Pages: 1138 - 1143

    

31. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer

    • Xin Zhao
    • Kai Mei
    • Qiu Li

    PHASE II STUDIES 12 January 2011 Pages: 1144 - 1149

    

32. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study

    • Soohyeon Lee
    • Sang Hyun Yoon
    • Hye Jin Choi

    PHASE II STUDIES 20 January 2011 Pages: 1150 - 1157

    

33. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium

    • Helen J. Mackay
    • Heather J. Au
    • Amit M. Oza

    PHASE II STUDIES 12 March 2011 Pages: 1158 - 1163

34. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research

    • Do-Youn Oh
    • Keun Wook Lee
    • Yung-Jue Bang

    PHASE II STUDIES 15 March 2011 Pages: 1164 - 1174

    

35. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

    • A. B. El-Khoueiry
    • R. K. Ramanathan
    • H. J. Lenz

    PHASE II STUDIES 22 March 2011 Pages: 1175 - 1183

    

36. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)

    • Beate Schultheis
    • Dirk Strumberg
    • Max E. Scheulen

    PHASE II STUDIES 12 April 2011 Pages: 1184 - 1192

    

37. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

    • Axel Le Cesne
    • Alejandro Yovine
    • George D. Demetri

    PHASE II STUDIES 12 April 2011 Pages: 1193 - 1202

    

38. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer

    • Daniel J. Renouf
    • Patricia A. Tang
    • Malcolm J. Moore

    PHASE II STUDIES 28 April 2011 Pages: 1203 - 1207

39. The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan

    • Marije Slingerland
    • Hans Gelderblom

    PHASE II STUDIES Open access 06 May 2011 Pages: 1208 - 1210

40. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

    • Manish R. Sharma
    • Kristen Wroblewski
    • Hedy L. Kindler

    PHASE II STUDIES 07 May 2011 Pages: 1211 - 1215

    

41. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

    • György Bodoky
    • Constanta Timcheva
    • N. C. Tebbutt

    PHASE II STUDIES 19 May 2011 Pages: 1216 - 1223

    

42. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials

    • Kohei Shitara
    • Junko Ikeda
    • Keitaro Matsuo

    PHASE III STUDIES 25 February 2011 Pages: 1224 - 1231

    

43. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

    • Craig Reynolds
    • Nicholas Di Bella
    • Lina Asmar

    PHASE III STUDIES 16 September 2011 Pages: 1232 - 1240

    

44. Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy

    • Youlia M. Kirova
    • Vincent Servois
    • Philippe Beuzeboc

    SHORT REPORT 14 December 2010 Pages: 1241 - 1243

    

45. Everolimus-related organizing pneumonia: a report establishing causality

    • Justine Frija
    • Dominique Joly
    • Pierre-Régis Burgel

    SHORT REPORT 29 December 2010 Pages: 1244 - 1247

    

46. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells

    • David Davidson
    • Yannick Coulombe
    • Lawrence Panasci

    Short Report 11 January 2011 Pages: 1248 - 1256

    

47. TRAIL shows potential cardioprotective activity

    • Barbara Toffoli
    • Stella Bernardi
    • Paola Secchiero

    SHORT REPORT 04 January 2011 Pages: 1257 - 1260

    

48. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor

    • Edgardo S. Santos
    • Jorge E. Gomez
    • Luis E. Raez

    REVIEW 25 February 2011 Pages: 1261 - 1269

    

49. Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

    • Timothy P. Burkholder
    • Joshua R. Clayton
    • James J. Starling

    Erratum 20 May 2011 Pages: 1270 - 1271

50. Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

    • György Bodoky
    • Constanta Timcheva
    • N. C. Tebbutt

    Erratum 26 July 2011 Pages: 1272 - 1273